Table 2.
Antimicrobial susceptibility in Neisseria gonorrhoeae isolates. Catalonia, Spain, 2016 − 2019
| Antimicrobials | Percentage of*: Susceptible/Susceptible, increase exposure/Resistant | ||||
|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | Total | |
| Ceftriaxone | 99.5/NA/0.5 | 98.5/NA/1.5 | 98.9/NA/1.1 | 99.1/NA/0.9 | 99.0/NA/1.0 |
| (n = 645) | (n = 888) | (n = 1,220) | (n = 1,608) | (n = 4,361) | |
| Cefixime | 97.0/NA/3 | 95.4/NA/4.6 | 97.7/NA/2.3 | 98.1/NA/1.9 | 97.5/NA/2.5 |
| (n = 164) | (n = 434) | (n = 1,042) | (n = 1,166) | (n = 2,806) | |
| Spectinomycin | 99.8/NA/0.2 | 100/NA/0 | 99.3/NA/0.7 | 99.3/NA/0.7 | 99.7/NA/0.3 |
| (n = 576) | (n = 821) | (n = 460) | (n = 433) | (n = 2,290) | |
| Ciprofloxacin | 44.7/0.7/54.5 | 45.9/2.3/51.8 | 42.5/1.0/56.5 | 37.1/1.2/61.7 | 41.6/1.3/57.1 |
| (n = 807) | (n = 1.120) | (n = 1,492) | (n = 1,896) | (n = 5,315) | |
| Penicillin | 10.5/67.6/21.9 | 10/74.4/15.6 | 11.1/68.3/20.6 | 13.2/65.9/21.0 | 11.5/68.6/19.9 |
| (n = 802) | (n = 1,080) | (n = 1,429) | (n = 1,854) | (n = 5,165) | |
| Tetracycline | 38.5/28.2/33.3 | 45.7/23.4/30.9 | 54.8/12.8/32.4 | 49.6/17.7/32.7 | 48.7/19.0/32.3 |
| (n = 291) | (n = 411) | (n = 564) | (n = 762) | (n = 2,028) | |
| Azithromycin | 89.2/4.8/6.1 | 89.4/4.9/5.8 | 81.3/10.4/8.3 | 77.6/6.4/16.0 | 82.7/7.0/10.3 |
| (n = 627) | (n = 903) | (n = 1,217) | (n = 1,654) | (n = 4,401) | |
Abbreviations: NA, not applicable
*The clinical breakpoints (susceptible, resistant) were as follows: ceftriaxone and cefixime (MIC ≤ 0.125 mg/L, MIC > 0.125 mg/L); ciprofloxacin (MIC ≤ 0.03 mg/L, MIC > 0.06 mg/L); spectinomycin (MIC ≤ 64 mg/L, MIC > 64 mg/L); penicillin (MIC ≤ 0.06 mg/L, MIC > 1.0 mg/L); tetracycline (MIC ≤ 0.5 mg/L, MIC > 1.0 mg/L); azithromycin (MIC ≤ 0.25 mg/L, MIC > 0.5 mg/L)